Skip to main content
Fig. 6 | Acta Neuropathologica Communications

Fig. 6

From: The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease

Fig. 6

PBT434 modulates α-synuclein transgenic animals. hA53T α-synuclein Tg mice consumed an average of 37 mg/kg/day in animal chow of PBT434 from 4 months of age for 4 months. a PBT434 preserved SNpc neurons (** P < 0.01, one-way ANOVA, Tukey post hoc); b PBT434 decreased SN iron measured by mass spectrometry (*P < 0.05, T-Test). SN tissue samples were homogenized to form a lysate, which was assayed by western blot and quantitated by optical density (OD) normalized to total protein (TP, Ponceau). c PBT434 did not reduced levels of the SDS soluble fraction of α- synuclein in the SN (Western blot, urea soluble fraction); d PBT434 reduced levels of the urea soluble fraction of α- synuclein in the SN (** p < 0.01; T-Test); E) PBT434 treatment increased SN ferroportin levels (*P < 0.05, T-Test)

Back to article page